A biomarker predicting unfavorable prognosis in malignant pleural mesothelioma: systemic immune–inflammation index

Yıl 2023, Cilt: 6 Sayı: 2, 389 - 393, 27.03.2023

Hüsnü Baykal , Filiz Çimen

https://doi.org/10.32322/jhsm.1242687

Öz

Aim: Malignant pleural mesothelioma (MPM) is an extremely mortal condition. Only a few prognostic biomarkers have been described for MPM. Our study looked into the association between patient survival and the Systemic Immune Inflammation Index (SII).
Material and Method: A total of 158 patients who were admitted to our hospital between January 2013 and December 2022, and had a histopathologically confirmed diagnosis of MPM were included in the study. Before treatment, hematological parameters and SII were determined. A Spearman's correlation analysis was performed to analyze the correlation of mean survival with hematological parameters.
Results: The study involved 158 patients in all. 70 patients had a history of smoking, the median age was 63 years, the mean survival time was 15.3 months, and 57.6% of the participants were men. The epithelioid type (84.2%) was the most prevalent histological subtype, and 29 patients had stage 4 illnesses. Of the participants, 84% had received chemotherapy, and 22% had received radiotherapy before. Among the 39 patients who had surgery, 5 had an extrapleural pneumonectomy. SII mean±sd was (1427.2±1207.3). The patients with stage 4 disease had significantly shorter survival (p=0.001). The patients who had surgery survived significantly longer (p=0.01). Hemoglobin (Hb) (r:0.21, p:0.01) and Hematocrit (Hct) (r:0.18, p:0.03) values showed weak positive correlations with mean survival. It was evident that mean survival got shorter as SII (r:-0.17, p:0.04) and neutrophil-lymphocyte ratio (NLR) (r:-0.19, p:0.02) values got higher. On the other hand, there was a strong positive association between mean survival and the lymphocyte-monocyte ratio (LMR) (r:0.21, p:0.01). When the parameters that had statistically significant differences among the groups were taken as control variables and the statistical analysis was re-performed, it was found that Hgb and Hct values as well as NLR and LMR ratios lost their significant correlations with survival. However, the SII ratio was still negatively correlated with survival (r:-0.16, p:0.04).
Conclusion: Pretreatment SII is a noninvasive and easy-to-calculate biomarker that predicts the prognosis of MPM. It is negatively correlated with mean survival regardless of the tumor stage and surgical management.

Anahtar Kelimeler

Malignant pleural mesothelioma, systemic immune-inflammation index, prognosis, survival

Kaynakça

• Cao S, Jin S, Cao J, et al. Malignant pericardial mesothelioma: a systematic review of current practice. Herz 2018; 43: 61–8.
• Zhang A, Cao S, Jin S, et al. Elevated aspartate aminotransferase and monocyte counts predict unfavorable prognosis in patients with malignant pleural mesothelioma. Neoplasma 2017; 64: 114–22.
• Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol2009; 27: 2081–90.
• Geltner C, Errhalt P, Baumgartner B, et al. Management of malignant pleural mesothelioma-part 1: epidemiology, diagnosis, and staging: consensus of the Austrian Mesothelioma Interest Group (AMIG). Wien Klin Wochensch 2016; 128: 611–7.
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140: 883–99.
• Shalapour S, Karin M. Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest 2015; 125: 3347–55.
• Bernhardt D, Aufderstrasse S, Konig L, et al. Impact of inflammatory markers on survival in patients with limited disease small-cell lung cancer undergoing chemoradiotherapy. Cancer Manag Res 2018; 10: 6563–9.
• Cao S, Jin S, Shen J, et al. Selected patients can benefit more from the management of etoposide and platinum-based chemotherapy and thoracic irradiation-a retrospective analysis of 707 small cell lung cancer patients. Oncotarget 2017; 8: 8657–9.
• Gao Y, Zhang H, Li Y, Wang D, Ma Y, Chen Q. Preoperative increased systemic immune-inflammation index predicts poor prognosis in patients with operable non-small cell lung cancer. Clin Chim Acta 2018; 484: 272–7.
• Henley SJ, Larson TC, Wu M, et al. Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003- 2008. Int J Occup Environ Health 2013; 19: 1–10.
• Ai J, Stevenson JP. Current issues in malignant pleural mesothelioma evaluation and management. Oncologist 2014; 19: 975–84.
• Kim J, Bhagwandin S, Labow DM. Malignant peritoneal mesothelioma: a review. Ann Transl Med 2017; 5: 236.
• De Perrot M, Feld R, Cho BCJ, et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 2009; 27: 1413–8.
• Ismail-Khan R, Robinson LA, Williams CC, Jr Garrett CR, Bepler G, Simon GR. Malignant pleural mesothelioma: a comprehensive review. Cancer Control 2006; 13: 255–63.
• Rusch VW, Giroux D, Kennedy C, et al. Initial analysis of the International Association for the Study of Lung Cancer Mesothelioma database. J Thorac Oncol 2012; 7: 1631–9.
• Ostan R, Lanzarini C, Pini E, et al. Inflammaging and cancer: a challenge for the Mediterranean diet. Nutrients 2015; 7: 2589–621.
• Belcher DA, Ju JA, Baek JH, et al. The quaternary state of polymerized human hemoglobin regulates oxygenation of breast cancer solid tumors: A theoretical and experimental study. PLoS One 2018; 13: e0191275.
• Peng F, Hu D, Lin X, et al. The monocyte to red blood cell count ratio is a strong predictor of postoperative survival in colorectal cancer patients: the Fujian prospective investigation of cancer (FIESTA) study. J Cancer 2017; 8: 967-75.
• Zou ZY, Liu HL, Ning N, Li SY, Du XH, Li R. Clinical significance of preoperative neutrophil-lymphocyte ratio and platelet lymphocyte ratio as prognostic factors for patients with colorectal cancer. Oncol Lett 2016; 11: 2241-8.
• Grieshober L, Graw S, Barnett MJ, et al. Pre-diagnosis neutrophil-to-lymphocyte ratio and mortality in individuals who develop lung cancer. Cancer Causes Control 2021; 32: 1227-36.
• Sahın F, Aslan AF. Relationship between inflammatory and biological markers and lung cancer. J Clin Med 2018; 7: 160.
• Wang Y, Huang D, Xu WY, et al. Prognostic value of pretreatment lymphocyte-to-monocyte ratio in non-small cell lung cancer: a meta-analysis. Oncol Res Treat 2019; 42: 523-31.
• Geng Y, Shao Y, He W, et al. Prognostic role of tumor-infiltrating lymphocytes in lung cancer: a meta-analysis. Cell Physiol Biochem 2015; 37: 1560-71.
• Gu XB, Tian T, Tian XJ, Zhang XJ. Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis. Sci Rep 2015; 5: 12493.
• Lin GN, Peng JW, Xiao JJ, et al. Prognostic impact of circulating monocytes and lymphocyte-to-monocyte ratio on previously untreated metastatic non-small cell lung cancer patients receiving platinum-based doublet. Med Oncol 2014; 31: 70.
• Gu X, Sun S, Gao XS, et al. Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3,430 patients. Sci Rep 2016; 6: 23893.
• Takada K, Takamori S, Matsubara T, et al. Clinical significance of preoperative inflammatory markers in non-small cell lung cancer patients: A multicenter retrospective study. Plos one 2020; 15: e0241580.
• Wang PX, Wang HJ, Liu JH, et al. A nomogram combining plasma fibrinogen and systemic immune‑inflammation index predicts survival in patients with resectable gastric cancer. Scientific Rep 2021; 11.
• Li J, Cao D, Huang Y, et al. The Prognostic and Clinicopathological Significance of Systemic Immune-Inflammation Index in Bladder Cancer. Cancer. Frontiers in immunology 2022; 13.
• Ji Y, Wang H. Prognostic prediction of systemic immune-inflammation index for patients with gynecological and breast cancers: a meta-analysis. World J Surg Oncol 2020; 18.1: 1-11.
• Wang D, Hu X, Xiao L, et al. Prognostic nutritional index and systemic immune-inflammation index predict the prognosis of patients with HCC. J Gastrointestin Surg 2021; 25.2: 421-7.